文献速递核素与放射性配体治疗放射性药物与辐射防护

99mTc-大颗粒聚合白蛋白肝肺分流研究显示镰状韧带动脉开放征象

99m Tc-Macroaggregated Albumin Liver Lung Shunt Study With Uptake Indicative of Patent Falciform Artery.
PubMed 文献 · Clin Nucl Med · 2022-09-30

本文报道在90Y选择性内放射治疗前的99mTc-大颗粒聚合白蛋白肝肺分流研究中,出现提示镰状韧带动脉开放的摄取表现,强调肝血管造影解剖变异需在治疗规划中加以识别。

要点

  • 90Y动脉内注射用于不可手术切除的局限性肝细胞癌等肝脏肿瘤的选择性内放射治疗。
  • 治疗前需经肝血管造影和99mTc-大颗粒聚合白蛋白肝肺分流研究进行定位。
  • SIR-Spheres治疗时肺分流分数大于20%为禁忌。

核心结论

  • 肝血管造影中可能存在解剖变异,若未加以考虑可导致并发症。

研究设计与样本

  • 本文为病例报道,描述99mTc-大颗粒聚合白蛋白肝肺分流研究中出现提示镰状韧带动脉开放的摄取表现。

主要发现

  • 99mTc-大颗粒聚合白蛋白肝肺分流研究出现提示镰状韧带动脉开放的摄取表现。

关键数值与推荐

  • SIR-Spheres治疗时肺分流分数大于20%为禁忌。

临床怎么用

  • 90Y治疗前需行肝血管造影和99mTc-大颗粒聚合白蛋白肝肺分流研究进行定位,治疗后行90Y SPECT/CT以确保靶向治疗。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Intra-arterial injection of radioactive isotope 90-yttrium 90 Y has been used for elective internal radiation therapy for the treatment of localized hepatocellular carcinoma deemed surgically unresectable. It has also been used to treat intrahepatic cholangiocarcinoma and colorectal cancer that has metastasized to the liver. To prepare for 90 Y treatment, preprocedural mapping via hepatic angiography and 99m Tc-macroaggregated albumin liver lung shunt study followed by postprocedural 90 Y SPECT/CT is essential to ensure a targeted therapy. Therapy is contraindicated if lung shunt fraction is greater than 20% for SIR-Spheres. Anatomic variation in hepatic angiography may be present that can lead to complications if unaccounted for.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Namous N, Kushner D, Dadparvar S, et al. 99m Tc-Macroaggregated Albumin Liver Lung Shunt Study With Uptake Indicative of Patent Falciform Artery. Clin Nucl Med. 2022. PMID: 36179332. doi:10.1097/RLU.0000000000004428

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。